nach oben

Erschienen in:

08.12.2018 | Original Article

Pain in patients with newly diagnosed or relapsed acute leukemia

verfasst von: Adir Shaulov, Gary Rodin, Gordana Popovic, Valerie B. Caraiscos, Lisa W. Le, Anne Rydall, Aaron D. Schimmer, Camilla Zimmermann

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Acute leukemia (AL) is associated with substantial morbidity and mortality. We assessed the prevalence and correlates of pain in patients with newly diagnosed or relapsed AL.

Methods

Patients with newly diagnosed or relapsed AL admitted to a comprehensive cancer center completed the Memorial Symptom Assessment Scale (MSAS), which assesses prevalence, severity, and distress associated with pain and other symptoms. Factors associated with severe pain were assessed using logistic regression. Two raters completed chart reviews in duplicate for patients with severe pain (MSAS severity ≥ 3/4) to determine the site of pain.

Results

Three hundred eighteen patients were recruited from January 2008 to October 2013: 245 (77.0%) had acute myeloid or acute promyelocytic leukemia (AML/APL) and 73 (23.0%) had acute lymphoblastic leukemia (ALL); 289 (90.9%) were newly diagnosed and 29 (9.1%) had relapsed disease. Pain was reported in 156/318 (49.2%), of whom 55/156 (35.3%) reported severe pain (≥ 3/4). Pain was associated with all psychological symptoms (all p < 0.005) and some physical symptoms. Severe pain was associated with younger age (p = 0.02), worse performance status (p = 0.04), ALL diagnosis (p = 0.04), and time from onset of chemotherapy (p = 0.03), with pain peaking at 4 weeks after chemotherapy initiation. The most common sites of severe pain were oropharynx (22; 40%), head (12; 21.8%), and abdomen (11; 20%). Only 3 patients (0.9%) were referred to the symptom control/palliative care team during the month prior to or following assessment.

Conclusions

Pain is frequent, distressing, and predictable in patients undergoing induction chemotherapy for AL. Further research is needed to assess the efficacy of early supportive care in this population.

Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136–1152. https://doi.org/10.1056/NEJMra1406184 CrossRefPubMed

Tallman MS, Altman JK (2009) How I treat acute promyelocytic leukemia. Blood 114:5126–5135. https://doi.org/10.1182/blood-2009-07-216457 CrossRefPubMed

Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7:e577. https://doi.org/10.1038/bcj.2017.53 CrossRefPubMedPubMedCentral

Bauduer F, Capdupuy C, Renoux M (2000) Characteristics of deaths in a department of oncohaematology within a general hospital. A study of 81 cases. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 8:302–306

Stalfelt AM, Brodin H, Pettersson S, Eklöf A (2003) The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain. Leuk Res 27:481–488CrossRefPubMed

LeBlanc TW, Smith JM, Currow DC (2015) Symptom burden of haematological malignancies as death approaches in a community palliative care service: a retrospective cohort study of a consecutive case series. Lancet Haematol 2:e334–e338. https://doi.org/10.1016/S2352-3026(15)00111-8 CrossRefPubMed

Fadul NA, El Osta B, Dalal S et al (2008) Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med 11:422–427. https://doi.org/10.1089/jpm.2007.0184 CrossRefPubMed

Niscola P, Tendas A, Scaramucci L, Giovaninni M, Cupelli L, de Sanctis V, Brunetti GA, Bondanini F, Palumbo R, Lamanda M, Battistini R, Cartoni C, Romani C, Arcuri E (2011) Pain in malignant hematology. Expert Rev Hematol 4:81–93. https://doi.org/10.1586/ehm.10.79 CrossRefPubMed

Zimmermann C, Yuen D, Mischitelle A, Minden MD, Brandwein JM, Schimmer A, Gagliese L, Lo C, Rydall A, Rodin G (2013) Symptom burden and supportive care in patients with acute leukemia. Leuk Res 37:731–736. https://doi.org/10.1016/j.leukres.2013.02.009 CrossRefPubMedPubMedCentral

10.

Rodin G, Yuen D, Mischitelle A, Minden MD, Brandwein J, Schimmer A, Marmar C, Gagliese L, Lo C, Rydall A, Zimmermann C (2013) Traumatic stress in acute leukemia. Psychooncology 22:299–307. https://doi.org/10.1002/pon.2092 CrossRefPubMed

11.

Rodin G, Deckert A, Tong E, Le LW, Rydall A, Schimmer A, Marmar CR, Lo C, Zimmermann C (2018) Traumatic stress in patients with acute leukemia: a prospective cohort study. Psychooncology 27:515–523. https://doi.org/10.1002/pon.4488 CrossRefPubMed

12.

Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H (1983) Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 140:734–739. https://doi.org/10.1176/ajp.140.6.734 CrossRefPubMed

13.

Karnofsky DA, Burchenal H (1949) The clinical evaluation of chemotherapeutic agents. In: McCloud CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191–205

14.

Rowe JM (2009) Optimal induction and post-remission therapy for AML in first remission. Hematol Am Soc Hematol Educ Program 2009:396–405. https://doi.org/10.1182/asheducation-2009.1.396 CrossRef

15.

Brandwein JM, Gupta V, Schuh AC, Schimmer AD, Yee K, Xu W, Messner HA, Lipton JH, Minden MD (2008) Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. Am J Hematol 83:54–58. https://doi.org/10.1002/ajh.21034 CrossRefPubMed

16.

Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, Testi AM, Mandelli F (1991) Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 9:1210–1214. https://doi.org/10.1200/JCO.1991.9.7.1210 CrossRef

17.

Huhmann IM, Watzke HH, Geissler K, Gisslinger H, Jäger U, Knöbl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kalhs P, Haas OA, Lechner K (1996) FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73:265–271CrossRefPubMed

18.

Portenoy RK, Thaler HT, Kornblith AB, Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L, Scher H (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer Oxf Engl 1990(30A):1326–1336

19.

Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KWL, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM (2009) Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 146:76–85. https://doi.org/10.1111/j.1365-2141.2009.07712.x CrossRefPubMed

20.

Deshields TL, Potter P, Olsen S, Liu J (2014) The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 22:1089–1096. https://doi.org/10.1007/s00520-013-2049-3 CrossRef

21.

Niscola P (2006) Opioids in pain management of blood-related malignancies. Ann Hematol 85:489–501CrossRefPubMed

22.

Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 25:420–429CrossRefPubMed

23.

Cataldo JK, Paul S, Cooper B, Skerman H, Alexander K, Aouizerat B, Blackman V, Merriman J, Dunn L, Ritchie C, Yates P, Miaskowski C (2013) Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer 13:6. https://doi.org/10.1186/1471-2407-13-6 CrossRefPubMedPubMedCentral

24.

Posternak V, Dunn LB, Dhruva A, Paul SM, Luce J, Mastick J, Levine JD, Aouizerat BE, Hammer M, Wright F, Miaskowski C (2016) Differences in demographic, clinical, and symptom characteristics and quality of life outcomes among oncology patients with different types of pain. Pain 157:892–900. https://doi.org/10.1097/j.pain.0000000000000456 CrossRefPubMedPubMedCentral

25.

Cheung WY, Le LW, Gagliese L, Zimmermann C (2011) Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 19:417–423. https://doi.org/10.1007/s00520-010-0865-2 CrossRef

26.

Visser MRM, Oort FJ, van Lanschot JJB, van der Velden J, Kloek JJ, Gouma DJ, Schwartz CE, Sprangers MAG (2013) The role of recalibration response shift in explaining bodily pain in cancer patients undergoing invasive surgery: an empirical investigation of the Sprangers and Schwartz model. Psychooncology 22:515–522. https://doi.org/10.1002/pon.2114 CrossRefPubMed

27.

Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Glick JH (1984) Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol Off J Am Soc Clin Oncol 2:865–870. https://doi.org/10.1200/JCO.1984.2.8.865 CrossRef

28.

Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G, Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON), German AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235–1248. https://doi.org/10.1056/NEJMoa0901409 CrossRefPubMed

29.

Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin M, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE, UK NCRI AML Study Group (2015) A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125:3878–3885. https://doi.org/10.1182/blood-2015-01-623447 CrossRefPubMedPubMedCentral

30.

Portugal R, Lyrio R, Loureiro M, Urago K, Bard J, Borchardt A, Garnica M, Nucci M (2017) Daunorubicin 90 mg/m2 in acute myeloid leukemia induction: increased toxicity in young patients. Clin Lymphoma Myeloma Leuk 17:527–531. https://doi.org/10.1016/j.clml.2017.06.018 CrossRefPubMed

31.

Sonis ST, Sonis AL, Lieberman A (1978) Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 1939(97):468–472CrossRef

32.

Hui D, Didwaniya N, Vidal M, Shin SH, Chisholm G, Roquemore J, Bruera E (2014) Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer 120:1572–1578. https://doi.org/10.1002/cncr.28614 CrossRefPubMed

33.

Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR (2011) Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med 25:630–641. https://doi.org/10.1177/0269216310391692 CrossRefPubMed

34.

Odejide OO, Salas Coronado DY, Watts CD, Wright AA, Abel GA (2014) End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract 10:e396–e403. https://doi.org/10.1200/JOP.2014.001537 CrossRefPubMedPubMedCentral

35.

Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, Bruera E (2015) Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists. Ann Oncol Off J Eur Soc Med Oncol 26:1440–1446. https://doi.org/10.1093/annonc/mdv028 CrossRef

36.

LeBlanc TW, O’Donnell JD, Crowley-Matoka M, Rabow MW, Smith CB, White DB, Tiver GA, Arnold RM, Schenker Y (2015) Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study. J Oncol Pract 11:e230–e238. https://doi.org/10.1200/JOP.2014.001859

37.

El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, Jackson VA, Telles J, Rhodes A, Spitzer TR, McAfee S, Chen YA, Lee SS, Temel JS (2016) Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA 316:2094–2103. https://doi.org/10.1001/jama.2016.16786

38.

Zimmermann C (2016) Palliative care for patients with hematological malignancies: time for a new model. Leuk Res 48:78–79. https://doi.org/10.1016/j.leukres.2016.07.012 CrossRefPubMed

39.

LeBlanc TW (2014) Palliative care and hematologic malignancies: old dog, new tricks? J Oncol Pract 10:e404–e407. https://doi.org/10.1200/JOP.2014.000968 CrossRefPubMed

40.

Othus M, Kantarjian H, Petersdorf S, Ravandi F, Godwin J, Cortes J, Pierce S, Erba H, Faderl S, Appelbaum FR, Estey E (2014) Declining rates of treatment-related mortality in patients with newly diagnosed AML given “intense” induction regimens: a report from SWOG and MD Anderson. Leukemia 28:289–292. https://doi.org/10.1038/leu.2013.176 CrossRefPubMed

Titel: Pain in patients with newly diagnosed or relapsed acute leukemia
verfasst von: Adir Shaulov
Gary Rodin
Gordana Popovic
Valerie B. Caraiscos
Lisa W. Le
Anne Rydall
Aaron D. Schimmer
Camilla Zimmermann
Publikationsdatum: 08.12.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 8/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4583-5

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Pain in patients with newly diagnosed or relapsed acute leukemia